Telo Genomics Corp., a biotech company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions. It provides telomere analysis platform with diagnostic and prognostic applications; and solutions with liquid biopsies and related technologies in oncogenic and neurological diseases. The company's lead application is Telo-MM, a solution that provides actionable information to professionals in the treatment of Multiple Myeloma, a form of blood cancer. Its solutions also include TeloView, a proprietary software platform used to quantify specific features of each patient's telomeres. The company serves healthcare professionals, drug developers, and clinical researchers. Telo Genomics Corp. has a collaboration agreement with the Mayo Clinic to validate its Telo-MM tests for multiple myeloma. Telo Genomics Corp. was incorporated in 2014 and is headquartered in Toronto, Canada.